CA3039413A1 - Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases - Google Patents

Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases Download PDF

Info

Publication number
CA3039413A1
CA3039413A1 CA3039413A CA3039413A CA3039413A1 CA 3039413 A1 CA3039413 A1 CA 3039413A1 CA 3039413 A CA3039413 A CA 3039413A CA 3039413 A CA3039413 A CA 3039413A CA 3039413 A1 CA3039413 A1 CA 3039413A1
Authority
CA
Canada
Prior art keywords
active ingredient
pharmaceutical composition
cannabinoid
minor
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3039413A
Other languages
English (en)
French (fr)
Inventor
Andrea Small-Howard
Helen TURNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GBS Global Biopharma Inc
Original Assignee
GBS Global Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GBS Global Biopharma Inc filed Critical GBS Global Biopharma Inc
Publication of CA3039413A1 publication Critical patent/CA3039413A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3039413A 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases Pending CA3039413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662406764P 2016-10-11 2016-10-11
US62/406,764 2016-10-11
PCT/US2017/055989 WO2018071452A1 (en) 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CA3039413A1 true CA3039413A1 (en) 2018-04-19

Family

ID=60382587

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039413A Pending CA3039413A1 (en) 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Country Status (8)

Country Link
US (3) US10653640B2 (cg-RX-API-DMAC10.html)
EP (1) EP3525823B1 (cg-RX-API-DMAC10.html)
JP (2) JP7225103B2 (cg-RX-API-DMAC10.html)
CN (2) CN109963595B (cg-RX-API-DMAC10.html)
AU (3) AU2017344040A1 (cg-RX-API-DMAC10.html)
CA (1) CA3039413A1 (cg-RX-API-DMAC10.html)
IL (1) IL265902B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018071452A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN110997006A (zh) 2017-05-08 2020-04-10 因美制药公司 眼部药物递送制剂
JP2020520966A (ja) 2017-05-22 2020-07-16 ジービーエス グローバル バイオファーマ，インコーポレイテッド Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
CN112543633A (zh) 2018-05-22 2021-03-23 Gbs全球生物制药公司 Trpv1调节中使用的大麻素和/或萜烯
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
AU2019413789B2 (en) * 2018-12-29 2025-05-29 Buzzelet Development And Technologies Ltd. Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof
CA3134764A1 (en) * 2019-04-24 2020-10-29 Eric Hsu Compositions and methods for use of cannabinoids for neuroprotection
WO2020264424A1 (en) * 2019-06-28 2020-12-30 Gbs Global Biopharma, Inc. Treatment of pain using allosteric modulator of trpv1
WO2021009266A1 (en) * 2019-07-17 2021-01-21 Zealand Pharma A/S Pharmaceutical composition for subcutaneous administration
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN113694049B (zh) * 2020-05-21 2022-11-22 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
US20220047541A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating parkinson's disease
AU2021327215A1 (en) * 2020-08-18 2023-05-04 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of cytokine release syndrome while preserving key anti-viral immune reactions
US20240226124A9 (en) * 2021-02-16 2024-07-11 Augusta University Research Institute, Inc. Cannabidiol for treating neurodegenerative diseases
EP4124336B1 (en) 2021-07-30 2023-10-25 Cannamedical Pharma GmbH Transmucosal patch comprising a cannabinoid and/or an opioid
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
EP4408404A4 (en) * 2021-09-28 2025-10-29 Gbs Global Biopharma Inc Formulations containing cannabinoids for Parkinsonian movement disorders
AU2024206205A1 (en) * 2023-01-04 2025-07-17 Florascience Inc. Cannabinoids for use in the treatment of a neurodegenerative disease or condition
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079963B1 (en) 1981-06-04 1986-08-27 Delaware Chemicals Corporation Pressurized container with dispensing pump
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
EP1067839A1 (en) 1998-04-08 2001-01-17 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CA2533400C (en) * 2001-02-14 2017-01-03 Gw Pharma Limited Cannabinoids pharmaceutical formulations
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
US20060241130A1 (en) 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
US8277781B2 (en) 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
WO2010127033A1 (en) 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
US9066910B2 (en) 2010-04-15 2015-06-30 Steven Rosenblatt Methods and compositions of cannabis extracts
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
WO2014145490A2 (en) * 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
BR112015028516A2 (pt) 2013-05-24 2017-07-25 Nestec Sa tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
US9763991B2 (en) * 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
WO2016133824A1 (en) 2015-02-16 2016-08-25 Axim Biotechnologies, Inc. Cosmetic and topical compositions comprising cannabigerol
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US10517911B2 (en) 2016-05-06 2019-12-31 Harvest Direct Enterprises Llc Manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals using representative/total/complete cannabis extractions (cannabis infused pills)

Also Published As

Publication number Publication date
AU2017344040A1 (en) 2019-04-18
JP2023058599A (ja) 2023-04-25
US20200338017A1 (en) 2020-10-29
EP3525823A1 (en) 2019-08-21
AU2025213702A1 (en) 2025-09-04
IL265902B2 (en) 2024-04-01
EP3525823B1 (en) 2024-04-24
CN109963595A (zh) 2019-07-02
WO2018071452A1 (en) 2018-04-19
US20180098948A1 (en) 2018-04-12
US20250108016A1 (en) 2025-04-03
US11980592B2 (en) 2024-05-14
AU2023222872A1 (en) 2023-09-21
CN115887440A (zh) 2023-04-04
IL265902B1 (en) 2023-12-01
IL265902A (en) 2019-06-30
US10653640B2 (en) 2020-05-19
JP7225103B2 (ja) 2023-02-20
CN109963595B (zh) 2023-02-03
JP2019530751A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
US20250108016A1 (en) Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
US20240269089A1 (en) Myrcene-containing complex mixtures targeting trpv1
EP3576724B1 (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US20230087359A1 (en) Cannabinoid compositions and methods of use thereof
US20200405657A1 (en) Treatment of pain using allosteric modulator of trpv1
US20240316002A1 (en) Cannabinoid-Containing Formulations for Parkinsonian Movement Disorders
HK40012464B (en) Cannabinoid-containing complex mixtures for the treatment of parkinson's disease
HK40012464A (en) Cannabinoid-containing complex mixtures for the treatment of parkinson's disease
HK40019031B (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
HK40019031A (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240829

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20250703

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250703

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250707

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250725

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250725

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260223

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260227

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260302

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260522

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728